Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00981682 · ClinicalTrials.gov registry record · Phase 3
Long Term Safety Assessment of SER120 in Patients With Nocturia
A Phase 3 study of Nocturia, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 376
- Enrollment target
- 1
- Study location
NCT00981682 is a Phase 3 study of Nocturia that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 376 participants, above the 275-participant average among 9 other Nocturia trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00981682, a Phase 3 study of Nocturia, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 376 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
Conditions Studied
Interventions
- DRUG SER120
Study Locations (1)
California
- Stephen M. Auerbach, MD - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00981682
The ClinicalTrials.gov registry entry for NCT00981682 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 275-participant average among 9 other Nocturia trials with a reported enrollment target (37% higher). The listed sponsor is Serenity Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nocturia appearing as the primary indexed condition, and to 1 intervention - of which SER120 is the first listed.
NCT00981682 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00981682 about?
NCT00981682 is a clinical study titled "Long Term Safety Assessment of SER120 in Patients With Nocturia". The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.
What is the current status of trial NCT00981682?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 376 participants. The study started on 2009-08. Estimated completion is 2011-08.
What conditions does trial NCT00981682 study?
This clinical trial studies the following conditions: Nocturia.
What interventions are being tested in trial NCT00981682?
The interventions under investigation include: SER120 (DRUG).
Who is sponsoring clinical trial NCT00981682?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00981682 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nocturia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia
COMPLETED · Phase 3
-
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
COMPLETED · Phase 3
-
An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults
COMPLETED · Phase 3
-
Mandibular Advancement Device and Changes in Nocturia
RECRUITING · NA
-
Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A
RECRUITING · Phase 4
-
Multi-center Trial to Improve Nocturia and Sleep in Older Adults
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.